160 related articles for article (PubMed ID: 28639341)
1. Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions.
Jost C; Stüber JC; Honegger A; Wu Y; Batyuk A; Plückthun A
Protein Sci; 2017 Sep; 26(9):1796-1806. PubMed ID: 28639341
[TBL] [Abstract][Full Text] [Related]
2. A designed ankyrin repeat protein evolved to picomolar affinity to Her2.
Zahnd C; Wyler E; Schwenk JM; Steiner D; Lawrence MC; McKern NM; Pecorari F; Ward CW; Joos TO; Plückthun A
J Mol Biol; 2007 Jun; 369(4):1015-28. PubMed ID: 17466328
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2.
Jost C; Schilling J; Tamaskovic R; Schwill M; Honegger A; Plückthun A
Structure; 2013 Nov; 21(11):1979-91. PubMed ID: 24095059
[TBL] [Abstract][Full Text] [Related]
4. Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells.
Siegler E; Li S; Kim YJ; Wang P
Hum Gene Ther; 2017 Sep; 28(9):726-736. PubMed ID: 28796529
[TBL] [Abstract][Full Text] [Related]
5. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
[TBL] [Abstract][Full Text] [Related]
6. DARPin-Based Crystallization Chaperones Exploit Molecular Geometry as a Screening Dimension in Protein Crystallography.
Batyuk A; Wu Y; Honegger A; Heberling MM; Plückthun A
J Mol Biol; 2016 Apr; 428(8):1574-88. PubMed ID: 26975886
[TBL] [Abstract][Full Text] [Related]
7. Selection, purification, and characterization of a HER2-targeting soluble designed ankyrin repeat protein by E. coli surface display using HER2-positive melanoma cells.
Chen X; Yu X; Song X; Liu L; Yi Y; Yao W; Gao X
Prep Biochem Biotechnol; 2018 Feb; 48(2):144-150. PubMed ID: 29313422
[TBL] [Abstract][Full Text] [Related]
8. Directed evolution of anti-HER2 DARPins by SNAP display reveals stability/function trade-offs in the selection process.
Houlihan G; Gatti-Lafranconi P; Lowe D; Hollfelder F
Protein Eng Des Sel; 2015 Sep; 28(9):269-79. PubMed ID: 26134501
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of HER3 extracellular domain 4 in complex with the designed ankyrin-repeat protein D5.
Radom F; Vonrhein C; Mittl PRE; Plückthun A
Acta Crystallogr F Struct Biol Commun; 2021 Jul; 77(Pt 7):192-201. PubMed ID: 34196609
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion.
Deyev SM; Oroujeni M; Garousi J; Gräslund T; Li R; Rosly AHB; Orlova A; Konovalova E; Schulga A; Vorobyeva A; Tolmachev V
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673831
[TBL] [Abstract][Full Text] [Related]
11. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
[TBL] [Abstract][Full Text] [Related]
12. Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice.
Sadri-Ardalani F; Ahmadi M; Hemmati A; Emami S; Farid S; Amiri MM; Jeddi-Tehrani M; Shabani M; Shokri F
Iran J Immunol; 2017 Jun; 14(2):99-110. PubMed ID: 28630381
[TBL] [Abstract][Full Text] [Related]
13. Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro.
Hosseini Ghatar R; Soltantoyeh T; Bahadori M; Khoshnoodi J; Golsaz Shirazi F; Jeddi Tehrani M; Amiri MM; Shokri F
Iran J Immunol; 2017 Sep; 14(3):200-214. PubMed ID: 28919583
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure and function of a DARPin neutralizing inhibitor of lactococcal phage TP901-1: comparison of DARPin and camelid VHH binding mode.
Veesler D; Dreier B; Blangy S; Lichière J; Tremblay D; Moineau S; Spinelli S; Tegoni M; Plückthun A; Campanacci V; Cambillau C
J Biol Chem; 2009 Oct; 284(44):30718-26. PubMed ID: 19740746
[TBL] [Abstract][Full Text] [Related]
15. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
Deyev SM; Vorobyeva A; Schulga A; Abouzayed A; Günther T; Garousi J; Konovalova E; Ding H; Gräslund T; Orlova A; Tolmachev V
Int J Biol Macromol; 2020 Feb; 145():216-225. PubMed ID: 31863835
[TBL] [Abstract][Full Text] [Related]
16. Highly specific hybrid protein DARPin-mCherry for fluorescent visualization of cells overexpressing tumor marker HER2/neu.
Mironova KE; Chernykh ON; Ryabova AV; Stremovskiy OA; Proshkina GM; Deyev SM
Biochemistry (Mosc); 2014 Dec; 79(12):1391-6. PubMed ID: 25716734
[TBL] [Abstract][Full Text] [Related]
17. DARPins: an efficient targeting domain for lentiviral vectors.
Münch RC; Mühlebach MD; Schaser T; Kneissl S; Jost C; Plückthun A; Cichutek K; Buchholz CJ
Mol Ther; 2011 Apr; 19(4):686-93. PubMed ID: 21224833
[TBL] [Abstract][Full Text] [Related]
18. Structural Basis for the Selective Inhibition of c-Jun N-Terminal Kinase 1 Determined by Rigid DARPin-DARPin Fusions.
Wu Y; Honegger A; Batyuk A; Mittl PRE; Plückthun A
J Mol Biol; 2018 Jul; 430(14):2128-2138. PubMed ID: 29126898
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for high-affinity HER2 receptor binding by an engineered protein.
Eigenbrot C; Ultsch M; Dubnovitsky A; Abrahmsén L; Härd T
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15039-44. PubMed ID: 20696930
[TBL] [Abstract][Full Text] [Related]
20. Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting.
Dreier B; Mikheeva G; Belousova N; Parizek P; Boczek E; Jelesarov I; Forrer P; Plückthun A; Krasnykh V
J Mol Biol; 2011 Jan; 405(2):410-26. PubMed ID: 21056576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
